SG11201811507YA - Crystalline salts of peptide epoxyketone immunoproteasome inhibitor - Google Patents
Crystalline salts of peptide epoxyketone immunoproteasome inhibitorInfo
- Publication number
- SG11201811507YA SG11201811507YA SG11201811507YA SG11201811507YA SG11201811507YA SG 11201811507Y A SG11201811507Y A SG 11201811507YA SG 11201811507Y A SG11201811507Y A SG 11201811507YA SG 11201811507Y A SG11201811507Y A SG 11201811507YA SG 11201811507Y A SG11201811507Y A SG 11201811507YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- peptide
- english
- june
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 title abstract 2
- 229940126097 immunoproteasome inhibitor Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 235000001543 Corylus americana Nutrition 0.000 abstract 1
- 240000007582 Corylus avellana Species 0.000 abstract 1
- 235000007466 Corylus avellana Nutrition 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662356287P | 2016-06-29 | 2016-06-29 | |
PCT/US2017/039961 WO2018005772A1 (en) | 2016-06-29 | 2017-06-29 | Crystalline salts of peptide epoxyketone immunoproteasome inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811507YA true SG11201811507YA (en) | 2019-01-30 |
Family
ID=59351084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811507YA SG11201811507YA (en) | 2016-06-29 | 2017-06-29 | Crystalline salts of peptide epoxyketone immunoproteasome inhibitor |
Country Status (24)
Country | Link |
---|---|
US (3) | US10836756B2 (pt) |
EP (1) | EP3478670B1 (pt) |
JP (2) | JP7132855B2 (pt) |
KR (2) | KR102655020B1 (pt) |
CN (1) | CN109863141B (pt) |
AU (1) | AU2017290139B2 (pt) |
CA (1) | CA3029032A1 (pt) |
CL (1) | CL2018003872A1 (pt) |
DK (1) | DK3478670T3 (pt) |
EA (1) | EA201990154A1 (pt) |
ES (1) | ES2944958T3 (pt) |
FI (1) | FI3478670T3 (pt) |
HR (1) | HRP20230533T1 (pt) |
HU (1) | HUE062106T2 (pt) |
IL (1) | IL263738B2 (pt) |
LT (1) | LT3478670T (pt) |
MX (1) | MX2018016387A (pt) |
PL (1) | PL3478670T3 (pt) |
PT (1) | PT3478670T (pt) |
RS (1) | RS64286B1 (pt) |
SG (1) | SG11201811507YA (pt) |
SI (1) | SI3478670T1 (pt) |
TW (1) | TWI751178B (pt) |
WO (1) | WO2018005772A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
US20220040192A1 (en) * | 2018-10-04 | 2022-02-10 | Kezar Life Sciences | Immunoproteasome inhibitor formulations |
WO2024140736A1 (zh) * | 2022-12-27 | 2024-07-04 | 上海美悦生物科技发展有限公司 | 三肽环氧酮化合物、药物组合物及其制备方法和用途 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
CA2504933C (en) | 2002-11-06 | 2012-10-16 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
NZ595196A (en) | 2005-11-09 | 2013-03-28 | Proteolix Inc | Peptide-based compounds for enzyme inhibition |
PL2041158T3 (pl) | 2006-06-19 | 2013-08-30 | Onyx Therapeutics Inc | Peptydowe epoksyketony do hamowania proteasomu |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
PL2207791T5 (pl) | 2007-10-04 | 2020-07-27 | Onyx Therapeutics, Inc. | Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych |
CN101525370A (zh) | 2008-03-06 | 2009-09-09 | 海南建邦制药科技有限公司 | 一种新型高效多肽合成缩合剂 |
AP2011005690A0 (en) | 2008-10-21 | 2011-06-30 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones. |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | 転移抑制のためのペプチドエポキシケトンの使用 |
NZ602872A (en) | 2010-04-07 | 2014-05-30 | Onyx Therapeutics Inc | Crystalline peptide epoxyketone immunoproteasome inhibitor |
US8609610B2 (en) | 2011-02-18 | 2013-12-17 | Trustees Of Dartmouth College | Inhibitors of the trypsin-like site of the proteasome and methods of use thereof |
ES2543923T3 (es) | 2011-05-02 | 2015-08-25 | Gilead Sciences, Inc. | Sales sólidas amorfas de Cobicistat (GS-9350) |
KR20190137963A (ko) | 2012-05-08 | 2019-12-11 | 오닉스 세라퓨틱스, 인크. | 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법 |
EP2867202B1 (en) | 2012-06-29 | 2017-08-09 | Nissan Chemical Industries, Ltd. | Method for producing stereoselective epoxyketone compound |
JP2016501831A (ja) | 2012-10-11 | 2016-01-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ケトアミド免疫プロテアソーム阻害剤 |
RU2015117581A (ru) | 2012-10-12 | 2016-12-10 | Ф. Хоффманн-Ля Рош Аг | Макроциклические кетоамидные ингибиторы иммунопротеасом |
AR095426A1 (es) * | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
KR102365509B1 (ko) * | 2013-03-14 | 2022-02-21 | 오닉스 세라퓨틱스, 인크. | 트리펩타이드 에폭시 케톤 프로테이스 억제제 |
WO2014152127A1 (en) | 2013-03-14 | 2014-09-25 | Onyx Therapeutics, Inc. | Dipeptide and tripeptide epoxy ketone protease inhibitors |
CN104710507B (zh) | 2013-12-11 | 2018-08-14 | 深圳翰宇药业股份有限公司 | 一种卡非佐米的制备方法 |
-
2017
- 2017-06-29 PL PL17740179.1T patent/PL3478670T3/pl unknown
- 2017-06-29 LT LTEPPCT/US2017/039961T patent/LT3478670T/lt unknown
- 2017-06-29 SI SI201731345T patent/SI3478670T1/sl unknown
- 2017-06-29 DK DK17740179.1T patent/DK3478670T3/da active
- 2017-06-29 SG SG11201811507YA patent/SG11201811507YA/en unknown
- 2017-06-29 KR KR1020197002873A patent/KR102655020B1/ko active IP Right Grant
- 2017-06-29 PT PT177401791T patent/PT3478670T/pt unknown
- 2017-06-29 EA EA201990154A patent/EA201990154A1/ru unknown
- 2017-06-29 HR HRP20230533TT patent/HRP20230533T1/hr unknown
- 2017-06-29 FI FIEP17740179.1T patent/FI3478670T3/fi active
- 2017-06-29 HU HUE17740179A patent/HUE062106T2/hu unknown
- 2017-06-29 TW TW106121808A patent/TWI751178B/zh active
- 2017-06-29 KR KR1020247010946A patent/KR20240046315A/ko not_active Application Discontinuation
- 2017-06-29 CN CN201780053406.8A patent/CN109863141B/zh active Active
- 2017-06-29 CA CA3029032A patent/CA3029032A1/en active Pending
- 2017-06-29 ES ES17740179T patent/ES2944958T3/es active Active
- 2017-06-29 US US16/312,614 patent/US10836756B2/en active Active
- 2017-06-29 EP EP17740179.1A patent/EP3478670B1/en active Active
- 2017-06-29 WO PCT/US2017/039961 patent/WO2018005772A1/en unknown
- 2017-06-29 IL IL263738A patent/IL263738B2/en unknown
- 2017-06-29 AU AU2017290139A patent/AU2017290139B2/en active Active
- 2017-06-29 RS RS20230418A patent/RS64286B1/sr unknown
- 2017-06-29 MX MX2018016387A patent/MX2018016387A/es unknown
- 2017-06-29 JP JP2018568267A patent/JP7132855B2/ja active Active
-
2018
- 2018-12-28 CL CL2018003872A patent/CL2018003872A1/es unknown
-
2020
- 2020-10-09 US US17/066,556 patent/US11479548B2/en active Active
-
2022
- 2022-05-11 JP JP2022078265A patent/JP2022106971A/ja active Pending
- 2022-09-27 US US17/953,935 patent/US11891383B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201808014SA (en) | Compositions, devices, and methods for cell separation | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
SG11201809714TA (en) | Piperidines as menin inhibitors | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
CA2859619C (en) | Bromodomain inhibitors | |
SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201407200TA (en) | Liquid formulation | |
SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201402986RA (en) | Kinase inhibitors | |
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201408509PA (en) | Racecadotril lipid compositions |